| Literature DB >> 32605368 |
Zachary Armstrong1, Chi-Lin Kuo2, Daniël Lahav2, Bing Liu2, Rachel Johnson1, Thomas J M Beenakker2, Casper de Boer2, Chung-Sing Wong2, Erwin R van Rijssel2, Marjoke F Debets2, Bogdan I Florea2, Colin Hissink2, Rolf G Boot2, Paul P Geurink3, Huib Ovaa3, Mario van der Stelt2, Gijsbert M van der Marel2, Jeroen D C Codée2, Johannes M F G Aerts2, Liang Wu1, Herman S Overkleeft2, Gideon J Davies1.
Abstract
Golgi mannosidase II (GMII) catalyzes the sequential hydrolysis of two mannosyl residues from GlcNAcMan5GlcNAc2 to produce GlcNAcMan3GlcNAc2, the precursor for all complex N-glycans, including the branched N-glycans associated with cancer. Inhibitors of GMII are potential cancer therapeutics, but their usefulness is limited by off-target effects, which produce α-mannosidosis-like symptoms. Despite many structural and mechanistic studies of GMII, we still lack a potent and selective inhibitor of this enzyme. Here, we synthesized manno-epi-cyclophellitol epoxide and aziridines and demonstrate their covalent modification and time-dependent inhibition of GMII. Application of fluorescent manno-epi-cyclophellitol aziridine derivatives enabled activity-based protein profiling of α-mannosidases from both human cell lysate and mouse tissue extracts. Synthesized probes also facilitated a fluorescence polarization-based screen for dGMII inhibitors. We identified seven previously unknown inhibitors of GMII from a library of over 350 iminosugars and investigated their binding modalities through X-ray crystallography. Our results reveal previously unobserved inhibitor binding modes and promising scaffolds for the generation of selective GMII inhibitors.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32605368 DOI: 10.1021/jacs.0c03880
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419